AMLX
Amylyx Pharmaceuticals Inc
NASDAQ: AMLX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$14.73
-3.09% today
Updated 2026-05-08
Market cap
$1.69B
P/E ratio
—
P/S ratio
0.66x
EPS (TTM)
$-1.48
Dividend yield
—
52W range
$4 – $19
Volume
1.1M
Amylyx Pharmaceuticals Inc (AMLX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-10.69M | $-36.70M | $-74.80M | $-179.87M | $11.92M | $-167.65M | $-123.34M |
| Capital expenditures | $151000.00 | $151000.00 | $353000.00 | $2.53M | $1.24M | $157000.00 | $138000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $108000.00 | $243000.00 | $3.14M | $21.71M | $37.16M | $33.04M | $27.64M |
| Free cash flow | $-10.84M | $-36.85M | $-75.15M | $-182.40M | $10.68M | $-167.80M | $-123.48M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $12.93M | — | — | — |